Exhibit99.1

MARIZYMEIS PLEASED TO ANNOUNCE THE

APPOINTMENTOF DAVID BARTHEL AS CEO

JUPITER,Fla., November 16, 2021 /PRNewswire/ — MarizymeInc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring ofMr. David Barthel as the Chief Executive Officer for Marizyme. In his role Mr. Barthel will look to advance the Company’s technologypipeline and stay committed to the commercialization efforts of DuraGraft in Europe and Asia while focusing on the FDA submissions forDuraGraft and MATLOC 1 in the US. In addition, Mr. Barthel will lead the Company through its financing initiatives, strengthening thefinancial position of the Company in preparation for an anticipated Nasdaq listing in 2022.

Mr.Barthel founded The SmartPill Corp. and led the company as CEO & President until its acquisition by medical device giant, Medtronic(Nasdaq:MDT). Mr. Barthel successfully took The SmartPill company, developing an innovative ingestible sensor-based capsule fordiagnosing GI motility disorders, from its initial patent, through the entire product development process, raising more than $70 millionin multiple funding rounds. Mr. Barthel led his team through multiple clinical trials, manufacturing, FDA approval, commercializationand successful insurance reimbursement. After the acquisition by Medtronic, Mr. Barthel joined the company as Area Vice President, GIHSoutheast Division.

Mostrecently, Mr. Barthel was CEO of Health Logic Interactive Inc. (“Health Logic”) and its wholly owned Subsidiary, MyHealth Logic Inc. (“My Health Logic”), a company focused on developing an innovative point-of-care lab-on-chip digitaldiagnostic device technologies for chronic kidney disease. In less than a year, Mr. Barthel led the Company from an initial patent pendingtechnology with proof-of-concept data to building an IP portfolio and further advancing our lab-on-chip technology platform. The Companyalso began development on its point-of-care device, MATLOC 1, which is expected to have a functional prototype ready for its clinicaltrials to take place in Q3 2022. Mr. Barthel was responsible for implementing product and software development partners, the preparationof an FDA pre-submission, leading discussions with several potential strategic partners, integrating a strong clinical and business team-basedculture, and a diverse Scientific Advisory Board. He has also developed the business plan around the utilization of multiple partnersfor commercialization with the potential for multiple revenue streams that will ensure eventual success of the device. My Health LogicInc., subsidiary of Health Logic which holds the MATLOC device technology and all accompanying agreements, is currently in the processof being acquired by Marizyme.

Mr.Barthel earned a Bachelor of Arts Degree from St. Norbert College in De Pere, Wi and an MBA from Lake Forest Graduate School of Managementin Lake Forest, II.

Dr.Dhaduk, (Chairman) of the Board of Directors, stated the following: “We are very excited about acquiring My Health Logic and DavidBarthel becoming our CEO. My Health Logic developed the MATLOC technology, an innovative technology that has strong potential to improvethe lives of millions of patients with chronic kidney disease. Bringing on the very dedicated and effective management group led by DavidBarthel will add strength to Marizyme’s current team.

Thisis a very strategic step for Marizyme to diversify and improve Marizyme’s current product portfolio by adding more innovative,platform technologies and a strong management team. We are looking forward to bringing these new technologies to the market to servea unique and unmet need in the chronic kidney and cardiac disease population.”

AboutMarizyme, Inc.

Marizymeis an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortalityand costs in the acute care space. The Company’s flagship product, DuraGraft^®, is an intra-operative vascular graftstorage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complicationsassociated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes bysignificantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approvedfor use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the developmentand marketing of products based on its clinically tested and previously patented protease based therapeutic Krillase^®platform. Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com.

Forward-LookingStatements

Thispress release may contain certain forward-looking statements, including those relating to the Marizyme’s product development, clinicaland regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies,potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensurethe information and assumptions on which these statements are based are current, reasonable, and complete. However, a variety of factors,many of which are beyond the Company’s control, affect the Company’s operations, performance, business strategy and resultsand there can be no assurances that the Company’s actual results will not differ materially from those indicated herein. Additionalwritten and oral forward-looking statements may be made by the Company from time to time. Forward-looking statements may be identifiedby the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,”“plan,” “believe,” “estimate,” “potential,” “predict,” “project,”“should,” “would” and similar expressions and the negatives of those terms. These statements relate to futureevents or our financial performance and involve known and unknown risks, including those risks set forth in the Company’s riskfactor disclosure in the reports that Marizyme files with the Securities and Exchange Commission (SEC File No. 000-53223), uncertainties,and other factors which may cause actual results, performance or achievements to be materially different from any future results, performanceor achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue relianceon such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publiclyupdate any forward-looking statement, whether as a result of new information, future events or otherwise.